Director/PDMR Shareholding

 

TIDMAKT 
 
RNS Number : 1435L 
Ark Therapeutics Group PLC 
30 April 2010 
 

30 April 2010 
 
 
 
                           Ark Therapeutics Group plc 
 
 
          Transaction by Person Discharging Managerial Responsibilities 
                          Disclosure Rules DTR 3.1.4R 
 
 
 
Ark Therapeutics Group plc (LSE: AKT) ("Ark" or the "Company") announces that it 
was informed on 23 April 2010 that Dr Nigel Parker, CEO, exercised options over 
260,000 ordinary Ark shares of 1 pence each on 23 April 2010 in London at an 
exercise price of 0.0001 pence per share.  The option, which was granted to Dr 
Parker in April 2000, was due to expire on 25 April 2010, if not exercised 
before then. These shares represent approximately 0.12% of the Company's issued 
share capital.  Following the purchase of these shares, Dr Parker will own 
3,154,579 ordinary Ark shares, representing 1.51% of the Company's issued share 
capital. 
 
 
 
 
Martyn Williams 
Company Secretary 
Ark Therapeutics Group plc 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSBBGDSBGXBGGG